BioNTech: Could Covid vaccine technology crack cancer?
BioNTech’s mRNA cancer trials started long before the pandemic, and have shown some early encouraging signals. …
Speaking on the BBC’s Sunday with Laura Kuenssberg, Prof Tureci said: “mRNA acts as a blueprint and allows you to tell the body to produce the drug or the vaccine… and when you use mRNA as a vaccine, the mRNA is a blueprint for the ‘wanted poster’ of the enemy – in this case cancer antigens which distinguish cancer cells from normal cells.”
About The Author
